Intracellular Reduction-Responsive Molecular Targeted Nanomedicine for Hepatocellular Carcinoma Therapy.

Ding, Lei; Zhang, Ping; Huang, Xu; Yang, Kunmeng; Liu, Xingkai; Yu, Zhenxiang

Ding, Lei; Zhang, Ping; Huang, Xu; Yang, Kunmeng; Liu, Xingkai; Yu, Zhenxiang.

Afiliação

Ding L; Department of Hepatobiliary and Pancreatic Surgery, The First Hospital of Jilin University, Changchun, China.
Zhang P; Department of Hepatobiliary and Pancreatic Surgery, The First Hospital of Jilin University, Changchun, China.
Huang X; Department of Hepatobiliary and Pancreatic Surgery, The First Hospital of Jilin University, Changchun, China.
Yang K; Department of Hepatobiliary and Pancreatic Surgery, The First Hospital of Jilin University, Changchun, China.
Liu X; Department of Hepatobiliary and Pancreatic Surgery, The First Hospital of Jilin University, Changchun, China.
Yu Z; Department of Respiration, The First Hospital of Jilin University, Changchun, China.

Front Pharmacol ; 12: 809125, 2021.

Article em En | MEDLINE | ID: mdl-35082681

Palavras-chave

hepatocellular carcinoma; lenvatinib; molecular targeted therapy; polypeptide; reduction-responsive nanomedicine

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Front Pharmacol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: China

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google